Leah H Rubin1, Pauline M Maki2, Gayle Springer2, Lorie Benning2, Kathryn Anastos2, Deborah Gustafson2, Maria C Villacres2, Xiong Jiang2, Adaora A Adimora2, Drenna Waldrop-Valverde2, David E Vance2, Hector Bolivar2, Christine Alden2, Eileen M Martin2, Victor G Valcour2. 1. From the Departments of Psychiatry (L.H.R., P.M.M.) and Psychology (P.M.M.), University of Illinois at Chicago; Department of Neurology (L.H.R.), Johns Hopkins University School of Medicine; Department and Epidemiology (G.S., L.B., C.A.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD; Albert Einstein College of Medicine and Montefiore Medical Center (K.A.), Bronx; Department of Neurology (D.G.), SUNY-Downstate Medical Center, Brooklyn, NY; University of Southern California (M.C.V.), Los Angeles; Department of Neuroscience (X.J.), Georgetown University Medical Center, Washington, DC; Division of Infectious Disease (A.A.A.), University of North Carolina at Chapel Hill; Nell Hodgson Woodruff School of Nursing (D.W.-V.), Emory University, Atlanta, GA; School of Nursing (D.E.V.), University of Alabama at Birmingham; University of Miami Miller School of Medicine (H.B.), FL; Department of Psychiatry (E.M.M.), Rush University Medical Center, Chicago, IL; and Memory and Aging Center (V.G.C.), Department of Neurology, University of California, San Francisco. lrubin1@jhmi.edu. 2. From the Departments of Psychiatry (L.H.R., P.M.M.) and Psychology (P.M.M.), University of Illinois at Chicago; Department of Neurology (L.H.R.), Johns Hopkins University School of Medicine; Department and Epidemiology (G.S., L.B., C.A.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD; Albert Einstein College of Medicine and Montefiore Medical Center (K.A.), Bronx; Department of Neurology (D.G.), SUNY-Downstate Medical Center, Brooklyn, NY; University of Southern California (M.C.V.), Los Angeles; Department of Neuroscience (X.J.), Georgetown University Medical Center, Washington, DC; Division of Infectious Disease (A.A.A.), University of North Carolina at Chapel Hill; Nell Hodgson Woodruff School of Nursing (D.W.-V.), Emory University, Atlanta, GA; School of Nursing (D.E.V.), University of Alabama at Birmingham; University of Miami Miller School of Medicine (H.B.), FL; Department of Psychiatry (E.M.M.), Rush University Medical Center, Chicago, IL; and Memory and Aging Center (V.G.C.), Department of Neurology, University of California, San Francisco.
Abstract
OBJECTIVE: To determine whether persistent viral suppression alters cognitive trajectories among HIV-infected (HIV+) women on combination antiretroviral therapy (cART) by investigating performance longitudinally in uninfected (HIV-) and 3 groups of HIV+ women: those with consistent viral suppression after continuous cART use (VS), those without consistent virologic suppression despite continuous cART use (NVS), and those without consistent virologic suppression after intermittent cART use (Int NVS). METHODS: Two hundred thirty-nine VS, 220 NVS, 172 Int NVS, and 301 HIV- women from the Women's Interagency HIV Study (WIHS) completed neuropsychological testing every 2 years for 3 visits between 2009 and 2013. Mixed-effects regressions were used to examine group differences on continuous T scores and categorical measures of impairment (T score <40). RESULTS: On global function, VS women demonstrated lower scores and were more likely to score in the impaired range than HIV- women (p = 0.01). These differences persisted over time (group × time, p > 0.39). VS women demonstrated lower learning and memory scores than HIV- women (p < 0.05) and lower attention/working memory and fluency scores than HIV- and NVS women (p < 0.05). Group differences in scores persisted over time. Categorically, VS women were more likely to be impaired on attention/working memory and executive function than HIV- women (p < 0.05). On motor skills, VS and NVS women showed a greater decline and were more likely to be impaired than HIV- women (p < 0.05). CONCLUSIONS: Cognitive difficulties remain among HIV+ women despite persistent viral suppression. In some instances, VS women are worse than NVS women, reinforcing the need for novel adjunctive therapies to attenuate cognitive problems.
OBJECTIVE: To determine whether persistent viral suppression alters cognitive trajectories among HIV-infected (HIV+) women on combination antiretroviral therapy (cART) by investigating performance longitudinally in uninfected (HIV-) and 3 groups of HIV+ women: those with consistent viral suppression after continuous cART use (VS), those without consistent virologic suppression despite continuous cART use (NVS), and those without consistent virologic suppression after intermittent cART use (Int NVS). METHODS: Two hundred thirty-nine VS, 220 NVS, 172 Int NVS, and 301 HIV- women from the Women's Interagency HIV Study (WIHS) completed neuropsychological testing every 2 years for 3 visits between 2009 and 2013. Mixed-effects regressions were used to examine group differences on continuous T scores and categorical measures of impairment (T score <40). RESULTS: On global function, VS women demonstrated lower scores and were more likely to score in the impaired range than HIV- women (p = 0.01). These differences persisted over time (group × time, p > 0.39). VS women demonstrated lower learning and memory scores than HIV- women (p < 0.05) and lower attention/working memory and fluency scores than HIV- and NVS women (p < 0.05). Group differences in scores persisted over time. Categorically, VS women were more likely to be impaired on attention/working memory and executive function than HIV- women (p < 0.05). On motor skills, VS and NVS women showed a greater decline and were more likely to be impaired than HIV- women (p < 0.05). CONCLUSIONS: Cognitive difficulties remain among HIV+ women despite persistent viral suppression. In some instances, VS women are worse than NVS women, reinforcing the need for novel adjunctive therapies to attenuate cognitive problems.
Authors: M A Cole; J B Margolick; C Cox; X Li; O A Selnes; E M Martin; J T Becker; H A Aronow; B Cohen; N Sacktor; E N Miller Journal: Neurology Date: 2007-10-03 Impact factor: 9.910
Authors: Michael K Keutmann; Raul Gonzalez; Pauline M Maki; Leah H Rubin; Jasmin Vassileva; Eileen M Martin Journal: J Clin Exp Neuropsychol Date: 2016-11-13 Impact factor: 2.475
Authors: James T Becker; Joanne Sanders; Sarah K Madsen; Ann Ragin; Lawrence Kingsley; Victoria Maruca; Bruce Cohen; Karl Goodkin; Eileen Martin; Eric N Miller; Ned Sacktor; Jeffery R Alger; Peter B Barker; Priyanka Saharan; Owen T Carmichael; Paul M Thompson Journal: Brain Imaging Behav Date: 2011-06 Impact factor: 3.978
Authors: Adriana Carvalhal; M John Gill; Scott L Letendre; Anita Rachlis; Tsegaye Bekele; Janet Raboud; Ann Burchell; Sean B Rourke Journal: J Neurovirol Date: 2015-11-16 Impact factor: 2.643
Authors: Leah H Rubin; Maria Pyra; Judith A Cook; Kathleen M Weber; Mardge H Cohen; Eileen Martin; Victor Valcour; Joel Milam; Kathryn Anastos; Mary A Young; Christine Alden; Deborah R Gustafson; Pauline M Maki Journal: J Neurovirol Date: 2015-09-24 Impact factor: 2.643
Authors: Erin E Sundermann; Robert K Heaton; Elizabeth Pasipanodya; Raeanne C Moore; Emily W Paolillo; Leah H Rubin; Ronald Ellis; David J Moore Journal: AIDS Date: 2018-11-28 Impact factor: 4.177
Authors: Pauline M Maki; Leah H Rubin; Gayle Springer; Eric C Seaberg; Ned Sacktor; Eric N Miller; Victor Valcour; Mary A Young; James T Becker; Eileen M Martin Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: Leah H Rubin; Gayle Springer; Eileen M Martin; Eric C Seaberg; Ned C Sacktor; Andrew Levine; Victor G Valcour; Mary A Young; James T Becker; Pauline M Maki Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: Elizabeth Vásquez; Ellen E Lee; Weihui Zhang; Xin Tu; David J Moore; María J Marquine; Dilip V Jeste Journal: Psychiatry Res Date: 2020-10-15 Impact factor: 3.222
Authors: Kendra K Radtke; Peter Bacchetti; Kathryn Anastos; Daniel Merenstein; Howard Crystal; Roksana Karim; Kathleen M Weber; Andrew Edmonds; Anandi N Sheth; Margaret A Fischl; David Vance; Ruth M Greenblatt; Leah H Rubin Journal: J Acquir Immune Defic Syndr Date: 2018-06-01 Impact factor: 3.731